Search
Shattuck Labs Inc
STTKAdd to Watchlist
7.050USD
+0.540+8.29%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
532.85MMarket Cap
LossP/E TTM
More Details of Shattuck Labs Inc Company
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Shattuck Labs Inc Info
Ticker SymbolSTTK
Company nameShattuck Labs Inc
IPO dateOct 09, 2020
CEOSchreiber (Taylor)
Number of employees44
Security typeOrdinary Share
Fiscal year-endOct 09
Address500 W. 5Th Street
CityAUSTIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78701
Phone15129004690
Websitehttps://www.shattucklabs.com/
Ticker SymbolSTTK
IPO dateOct 09, 2020
CEOSchreiber (Taylor)
Company Executives of Shattuck Labs Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
122.22K
+20.95%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
93.37K
+12.68%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
122.22K
+20.95%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
93.37K
+12.68%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
FAQs
Who are the top five shareholders of Shattuck Labs Inc?
The top five shareholders of Shattuck Labs Inc are: Dr. Taylor Schreiber, M.D., Ph.D.
How many institutions hold shares of Shattuck Labs Inc (STTK)?
As of 2026Q1, 189 institutions hold shares of Shattuck Labs Inc, with a combined market value of approximately 50.41M, accounting for 65.78% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 9741871.00.